Published in AIDS Weekly, March 30th, 1998
"Considering that the toxicity profile of the two compounds is completely different, the choice of anti-cytomegalovirus (CMV) agent should be tailored to the individual patient according to the presence of either relative or absolute contraindication to one of the two drugs, as well as viral resistance, toxicity, concomitant therapies, and patient preference," F. Parente and colleagues wrote ("Treatment of Cytomegalovirus Esophagitis in Patients with Acquired Immune...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.